Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	99.6	83.57	72.05	67.45	59.26
Revenue Growth (YoY)	19.18%	15.99%	6.82%	13.83%	28.01%
Cost of Revenue	38.01	32.79	29.25	25.96	23.98
Gross Profit	61.59	50.78	42.8	41.49	35.27
Selling, General & Admin	47.84	51.42	56.6	64.73	51.71
Research & Development	6.02	4.96	4.83	3.83	3.42
Operating Expenses	53.86	56.38	61.43	68.56	55.13
Operating Income	7.73	-5.6	-18.63	-27.07	-19.85
Interest Expense	-	-	-	-0.06	-0.07
Interest & Investment Income	1.13	0.66	0	-	-
EBT Excluding Unusual Items	8.86	-4.94	-18.63	-27.13	-19.93
Other Unusual Items	-	-	2.09	-	-
Pretax Income	8.86	-4.94	-16.54	-27.13	-19.93
Income Tax Expense	0.31	-	-	-	-
Earnings From Continuing Operations	8.55	-4.94	-16.54	-27.13	-19.93
Net Income	8.55	-4.94	-16.54	-27.13	-19.93
Net Income to Common	8.55	-4.94	-16.54	-27.13	-19.93
Shares Outstanding (Basic)	76	75	70	67	61
Shares Outstanding (Diluted)	78	75	70	67	61
Shares Change (YoY)	4.19%	7.54%	3.79%	10.02%	7.03%
EPS (Basic)	0.11	-0.07	-0.24	-0.40	-0.33
EPS (Diluted)	0.11	-0.07	-0.24	-0.40	-0.33
Free Cash Flow	11.95	6.97	-15.43	-24.57	-10.72
Free Cash Flow Per Share	0.15	0.09	-0.22	-0.37	-0.18
Gross Margin	61.83%	60.76%	59.40%	61.51%	59.53%
Operating Margin	7.76%	-6.70%	-25.85%	-40.14%	-33.51%
Profit Margin	8.58%	-5.91%	-22.96%	-40.22%	-33.63%
Free Cash Flow Margin	11.99%	8.34%	-21.42%	-36.43%	-18.10%
EBITDA	8.54	-4.57	-17.57	-25.96	-18.74
EBITDA Margin	8.58%	-5.47%	-24.39%	-38.48%	-31.62%
D&A For EBITDA	0.81	1.03	1.06	1.12	1.11
EBIT	7.73	-5.6	-18.63	-27.07	-19.85
EBIT Margin	7.76%	-6.70%	-25.85%	-40.14%	-33.51%
Effective Tax Rate	3.44%	-	-	-	-
Advertising Expenses	11.1	10.3	11.4	12.5	7.4

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.